Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis

Cancer immunology research

Volumn 2, Issue 1, 2014, Pages 15-18

  Min, Le ^a   Hodi, F Stephen ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; MONOCLONAL ANTIBODY; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR;

ANTAGONISTS AND INHIBITORS; CASE REPORT; HUMAN; HYPOTHYROIDISM; MALE; MELANOMA; MIDDLE AGED; MUCOSA; PATHOLOGY; RHABDOMYOLYSIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CTLA-4 ANTIGEN; HUMANS; HYPOTHYROIDISM; MALE; MELANOMA; MIDDLE AGED; MUCOUS MEMBRANE; PROGRAMMED CELL DEATH 1 RECEPTOR; RHABDOMYOLYSIS; TREATMENT OUTCOME;

EID: 84907996539     PISSN: None     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-13-0146     Document Type: Article

References (0)